# Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

> **NCT04773756** · PHASE4 · COMPLETED · sponsor: **Alexandria University** · enrollment: 54 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Sofosbuvir 400 MG/ Daclatasvir 60mg

## Key facts

- **NCT ID:** NCT04773756
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-01
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-12-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04773756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04773756, "Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04773756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*